Radiofrequency Ablation Accompanied With Spontaneous Sorafenib Administration in the Treatment of Early to Intermediate Stage Hepatocellular Carcinoma: a Prospective Multicenter Cohort Study.(REASSESS)
Phase of Trial: Phase III
Latest Information Update: 06 Mar 2019
Price : $35 *
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms REASSESS
- 27 Mar 2017 Planned End Date changed from 1 Dec 2015 to 1 Dec 2018.
- 27 Mar 2017 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2018.
- 27 Mar 2017 Status changed from not yet recruiting to recruiting.